Podcast

OnFocus Podcast: Michael Hoey

April 27, 2022

Francis Medical Founder and Chief Technology Officer, Michael Hoey, was recently featured on OnFocus, a podcast by The Focal Therapy Clinic in the UK.

Click below to hear Michael talk about his personal journey into discovering and developing water vapor therapy for treating the prostate and why he’s so committed to innovating in this space.


Original episode post and transcript
Supplemental Article: Key Trends Driving Progress in Focal Therapy

Learn more about water vapor therapy

Share this post

Recent Posts

Francis Medical Announces First Commercial Vanquish® Procedure to Ablate Prostate Tissue in the Midwest

April 21st, 2026|

Minneapolis [April 21, 2026] – Francis Medical, Inc., a privately held medical device company based out of Maple Grove, MN, today announced that Aaron Milbank, MD. of Minnesota Urology has successfully completed the first commercial procedure in the Midwest using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue.

Francis Medical Announces Further Commercial Expansion of Vanquish® Water Vapor Ablation with First Commercial Procedures to Ablate Targeted Prostate Tissue in the Southeast

April 16th, 2026|

Minneapolis, MN [April 16, 2026] – Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the first commercial procedures performed using the Vanquish® Water Vapor Ablation System in the Southeast, a minimally invasive technology designed to ablate targeted prostate tissue.

Francis Medical Announces First Commercial Vanquish® Procedure on the East Coast for Prostate Tissue Ablation

March 25th, 2026|

Minneapolis, MN [March. 25, 2026] – Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) procedure on the East Coast using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue while potentially helping to preserve urinary and sexual function.